Значения термина glucocorticosteroid на английском

Iatrogenic osteoporosis is a very common secondary osteoporosis is found in patients treated with large dosage of glucocorticosteroid of long duration.

The efficacy of a glucocorticosteroid-inducible promoter was assessed in controlling transgene expression following lentivirus-mediated gene transfer to ovine and human corneas.

The duration of treatment of primary disease with glucocorticosteroid is 1 to 3.5 years, with the average of 1.56 years.

At presentation, all patients except one had been inappropriately treated with glucocorticosteroid (insufficiently dosed or tapered too fast) for longer than 2 weeks.

The mechanisms appear to involve effects at the cell membrane as well as nuclear actions mediated by intracellular mineralo- and glucocorticosteroid receptors (MR and GR).

Topical glucocorticosteroid treatment abolished this increase in nasal symptoms and TAME activity (p less than 0.05 for all treatment alternatives).

In the active treatment alternatives, the glucocorticosteroid treatment was started 48, 12 or 2 hours before or 2 hours after the initial allergen challenge.

Conclusions: Transfersome may significantly improve the risk-benefit ratio of topically applied glucocorticosteroids.

Glucocorticosteroids are the most common first-line treatment for ECRS with nasal polyps.

Glucocorticosteroids are highly effective in controlling inflammation and the molecular mechanisms involved are now becoming clear.

Glucocorticosteroid treatment may offer some benefits.

This knowledge is useful for the further development of glucocorticosteroids with desirable action spectrum and with minimal side effects.

The ability of glucocorticosteroids to inhibit tissue eosinophilia may be an important feature of their anti-inflammatory action in allergic diseases.

Topical glucocorticosteroids were incorporated into nanocarrier-based formulations, to overcome side effects of conventional formulations and to achieve maximum skin deposition.

However, if proteinuria does not decrease significantly within 3 months from the beginning of this treatment, administration of glucocorticosteroids is recommended.

Aim: Topical glucocorticosteroids are administered to virtually every corneal transplant recipient, but irreversible immunological rejection remains the leading cause of graft failure.